Helvecardins A and B, novel glycopeptide antibiotics. III. Biological properties.
Helvecardins (HVCs) A and B were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), but they were inactive against Gram-negative bacteria and fungi. Though HVC A showed only slightly stronger antimicrobial activity than beta-avoparcin (AVP), its in vivo protective activity against S. aureus infection in mice was greatly superior to AVP.
Takeuchi
M
M
Fermentation Research laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Katayama
T
T
Inukai
M
M
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006020:Glycopeptides / Q000494:pharmacology; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D007928:Lethal Dose 50; D016106:Methicillin Resistance; D051379:Mice; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D006020:Glycopeptides; C068812:helvecardin A; C068813:helvecardin B; D014640:Vancomycin; C016249:avoparcin